{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:15Z","timestamp":1792652115946,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/06138-0"],"award-info":[{"award-number":["2021\/06138-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/08260-8, 2024\/07723-2"],"award-info":[{"award-number":["2021\/08260-8, 2024\/07723-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Epigenetic modifications significantly influence gene expression and play crucial roles in various biological processes, including carcinogenesis. This study investigates the effects of novel purine-benzohydroxamate compounds, particularly\n                    <jats:bold>4<\/jats:bold>\n                    \u2009\n                    <jats:bold>f<\/jats:bold>\n                    , as hybrid kinase\/histone deacetylase (HDAC) inhibitors in hematological malignancies, focusing on acute myeloid leukemia (AML). Our results demonstrate that these compounds selectively reduce cell viability in blood cancer cells, with inhibitory concentration values indicating higher potency against neoplastic cells compared to normal leukocytes. Mechanistically,\n                    <jats:bold>4<\/jats:bold>\n                    \u2009\n                    <jats:bold>f<\/jats:bold>\n                    induces apoptosis and cell cycle arrest, promoting differentiation in leukemia cells, while effectively inhibiting HDAC activity. Furthermore,\n                    <jats:bold>4<\/jats:bold>\n                    \u2009\n                    <jats:bold>f<\/jats:bold>\n                    enhances the therapeutic efficacy of venetoclax, a BCL2 inhibitor, in AML models sensitive and resistant to this drug. The combination treatment significantly increases apoptosis and reduces cell viability, suggesting a synergistic effect that may overcome drug resistance. This study provides valuable insights into the potential of HDAC inhibitors, particularly\n                    <jats:bold>4<\/jats:bold>\n                    \u2009\n                    <jats:bold>f<\/jats:bold>\n                    , as a promising therapeutic strategy for treating resistant hematological malignancies. Our findings underscore the importance of further exploring hybrid kinase\/HDAC inhibitors in combination therapies to improve outcomes in patients with acute leukemias and other hematological malignancies.\n                  <\/jats:p>","DOI":"10.1038\/s41420-025-02446-4","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:19:37Z","timestamp":1743891577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors"],"prefix":"10.1038","volume":"11","author":[{"given":"Jorge Antonio Elias Godoy","family":"Carlos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-7787","authenticated-orcid":false,"given":"Mauricio Temotheo","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5498-7539","authenticated-orcid":false,"given":"Keli","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Costa","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"de Barros Waitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Veras","family":"Costa-Lotufo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Parise-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8109","authenticated-orcid":false,"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"2446_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nbt.1685","volume":"28","author":"A Portela","year":"2010","unstructured":"Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057\u201368.","journal-title":"Nat Biotechnol"},{"key":"2446_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41576-020-0270-8","volume":"21","author":"Z Dai","year":"2020","unstructured":"Dai Z, Ramesh V, Locasale JW. The evolving metabolic landscape of chromatin biology and epigenetics. Nat Rev Genet. 2020;21:737\u201353.","journal-title":"Nat Rev Genet"},{"key":"2446_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2024","unstructured":"Sadida HQ, Abdulla A, Marzooqi SA, Hashem S, Macha MA, Akil ASA, et al. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Transl Oncol. 2024;39:101821.","journal-title":"Transl Oncol"},{"key":"2446_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.292","volume":"4","author":"R Liu","year":"2023","unstructured":"Liu R, Wu J, Guo H, Yao W, Li S, Lu Y, et al. Post-translational modifications of histones: mechanisms, biological functions, and therapeutic targets. MedComm (2020). 2023;4:e292.","journal-title":"MedComm (2020)"},{"key":"2446_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrg2540","volume":"10","author":"H Cedar","year":"2009","unstructured":"Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10:295\u2013304.","journal-title":"Nat Rev Genet"},{"key":"2446_CR6","doi-asserted-by":"publisher","first-page":"8894","DOI":"10.3390\/ijms21238894","volume":"21","author":"PK Rajan","year":"2020","unstructured":"Rajan PK, Udoh UA, Sanabria JD, Banerjee M, Smith G, Schade MS, et al. The role of histone acetylation-\/methylation-mediated apoptotic gene regulation in hepatocellular carcinoma. Int J Mol Sci. 2020;21:8894.","journal-title":"Int J Mol Sci"},{"key":"2446_CR7","doi-asserted-by":"publisher","first-page":"972312","DOI":"10.3389\/fendo.2022.972312","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang J, Song C, Zhan X. The role of protein acetylation in carcinogenesis and targeted drug discovery. Front Endocrinol (Lausanne). 2022;13:972312.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2446_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.semcancer.2021.03.001","volume":"85","author":"F Dang","year":"2022","unstructured":"Dang F, Wei W. Targeting the acetylation signaling pathway in cancer therapy. Semin Cancer Biol. 2022;85:209\u201318.","journal-title":"Semin Cancer Biol"},{"key":"2446_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17:37.","journal-title":"J Hematol Oncol"},{"key":"2446_CR10","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W, et al. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B. 2023;13:2425\u201363.","journal-title":"Acta Pharm Sin B"},{"key":"2446_CR11","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2446_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","volume":"6","author":"M New","year":"2012","unstructured":"New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6:637\u201356.","journal-title":"Mol Oncol"},{"key":"2446_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19:5.","journal-title":"Mol Cancer"},{"key":"2446_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","volume":"96","author":"V Wachholz","year":"2022","unstructured":"Wachholz V, Mustafa AM, Zeyn Y, Henninger SJ, Beyer M, Dzulko M, et al. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022;96:177\u201393.","journal-title":"Arch Toxicol"},{"key":"2446_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbrc.2023.09.023","volume":"680","author":"Y Deng","year":"2023","unstructured":"Deng Y, Cheng Q, He J. HDAC inhibitors: Promising agents for leukemia treatment. Biochem Biophys Res Commun 2023;680:61\u201372.","journal-title":"Biochem Biophys Res Commun"},{"key":"2446_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107480","volume":"140","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, Kazmierczak M, Wierzbowska A, Fong CY, Keng MK, Ballinari G, et al. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study. Leuk Res. 2024;140:107480.","journal-title":"Leuk Res"},{"key":"2446_CR17","doi-asserted-by":"publisher","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","volume":"8","author":"R Roy","year":"2023","unstructured":"Roy R, Ria T, RoyMahaPatra D, Sk UH. Single inhibitors versus dual inhibitors: role of HDAC in cancer. ACS Omega. 2023;8:16532\u201344.","journal-title":"ACS Omega"},{"key":"2446_CR18","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1021\/acs.jmedchem.8b00189","volume":"62","author":"Y Luan","year":"2019","unstructured":"Luan Y, Li J, Bernatchez JA, Li R. Kinase and histone deacetylase hybrid inhibitors for cancer therapy. J Med Chem. 2019;62:3171\u201383.","journal-title":"J Med Chem"},{"key":"2446_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115935","volume":"263","author":"KB Waitman","year":"2024","unstructured":"Waitman KB, de Almeida LC, Primi MC, Carlos J, Ruiz C, Kronenberger T, et al. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. Eur J Med Chem. 2024;263:115935.","journal-title":"Eur J Med Chem"},{"key":"2446_CR20","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3:4326\u201335.","journal-title":"Blood Adv"},{"key":"2446_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2446_CR22","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/blood-2010-05-260117","volume":"116","author":"JM Rowe","year":"2010","unstructured":"Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood. 2010;116:3147\u201356.","journal-title":"Blood"},{"key":"2446_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3324\/haematol.2022.280802","volume":"108","author":"S Jaramillo","year":"2023","unstructured":"Jaramillo S, Schlenk RF. Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica. 2023;108:342\u201352.","journal-title":"Haematologica"},{"key":"2446_CR24","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel G, Weber D, Fromm E, Erhardt S, Lubbert M, Fiedler W, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96:1993\u20132003.","journal-title":"Ann Hematol"},{"key":"2446_CR25","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387.","journal-title":"Blood"},{"key":"2446_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","volume":"32","author":"VA Guerra","year":"2019","unstructured":"Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pr Res Clin Haematol. 2019;32:145\u201353.","journal-title":"Best Pr Res Clin Haematol"},{"key":"2446_CR27","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1053\/j.seminoncol.2008.04.008","volume":"35","author":"C Plass","year":"2008","unstructured":"Plass C, Oakes C, Blum W, Marcucci G. Epigenetics in acute myeloid leukemia. Semin Oncol. 2008;35:378\u201387.","journal-title":"Semin Oncol"},{"key":"2446_CR28","doi-asserted-by":"crossref","unstructured":"San Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC Inhibitors in Acute Myeloid Leukemia. Cancers (Basel) 2019;11.","DOI":"10.3390\/cancers11111794"},{"key":"2446_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.seminhematol.2018.08.001","volume":"56","author":"SF Cai","year":"2019","unstructured":"Cai SF, Levine RL. Genetic and epigenetic determinants of AML pathogenesis. Semin Hematol. 2019;56:84\u201389.","journal-title":"Semin Hematol"},{"key":"2446_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13\u201318.","journal-title":"Cancer Cell"},{"key":"2446_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.1787609","volume":"23","author":"SL Berger","year":"2009","unstructured":"Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781\u20133.","journal-title":"Genes Dev"},{"key":"2446_CR32","first-page":"328","volume":"11","author":"FA Lagunas-Rangel","year":"2017","unstructured":"Lagunas-Rangel FA, Chavez-Valencia V, Gomez-Guijosa MA, Cortes-Penagos C. Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res. 2017;11:328\u201339.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"2446_CR33","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247\u201352.","journal-title":"Oncologist"},{"key":"2446_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","volume":"280","author":"P Atadja","year":"2009","unstructured":"Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280:233\u201341.","journal-title":"Cancer Lett"},{"key":"2446_CR35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168:811\u20139.","journal-title":"Br J Haematol"},{"key":"2446_CR36","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","volume":"12","author":"F Giles","year":"2006","unstructured":"Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628\u201335.","journal-title":"Clin Cancer Res"},{"key":"2446_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","volume":"81","author":"P Gimsing","year":"2008","unstructured":"Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81:170\u20136.","journal-title":"Eur J Haematol"},{"key":"2446_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bjh.17080","volume":"193","author":"S Mithraprabhu","year":"2021","unstructured":"Mithraprabhu S, Kalff A, Gartlan KH, Savvidou I, Khong T, Ramachandran M, et al. Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma. Br J Haematol. 2021;193:160\u201370.","journal-title":"Br J Haematol"},{"key":"2446_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0801-5","volume":"17","author":"Q Jiao","year":"2018","unstructured":"Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17:36.","journal-title":"Mol Cancer"},{"key":"2446_CR40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637\u201358.","journal-title":"Nat Rev Cancer"},{"key":"2446_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6:201.","journal-title":"Signal Transduct Target Ther"},{"key":"2446_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2174\/092986708783503212","volume":"15","author":"A Petrelli","year":"2008","unstructured":"Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008;15:422\u201332.","journal-title":"Curr Med Chem"},{"key":"2446_CR43","doi-asserted-by":"publisher","first-page":"8336","DOI":"10.1021\/acs.jmedchem.7b00678","volume":"60","author":"L Yao","year":"2017","unstructured":"Yao L, Mustafa N, Tan EC, Poulsen A, Singh P, Duong-Thi MD, et al. Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat. J Med Chem. 2017;60:8336\u201357.","journal-title":"J Med Chem"},{"key":"2446_CR44","doi-asserted-by":"publisher","first-page":"7874","DOI":"10.1021\/jm5006463","volume":"57","author":"A Anighoro","year":"2014","unstructured":"Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57:7874\u201387.","journal-title":"J Med Chem"},{"key":"2446_CR45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","volume":"20","author":"MM Attwood","year":"2021","unstructured":"Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schioth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20:839\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"2446_CR46","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1182\/blood-2002-06-1714","volume":"101","author":"G Del Poeta","year":"2003","unstructured":"Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, et al. Amount of spontaneous apoptosis detected by Bax\/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2003;101:2125\u201331.","journal-title":"Blood"},{"key":"2446_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341.","journal-title":"Cell Stem Cell"},{"key":"2446_CR48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328.","journal-title":"Lancet Oncol"},{"key":"2446_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"2446_CR50","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"2446_CR51","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM, et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020;38:3506\u201317.","journal-title":"J Clin Oncol"},{"key":"2446_CR52","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021;8:e552\u2013e561.","journal-title":"Lancet Haematol"},{"key":"2446_CR53","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"2446_CR54","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42:1499\u2013508.","journal-title":"J Clin Oncol"},{"key":"2446_CR55","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021;39:2768\u201378.","journal-title":"J Clin Oncol"},{"key":"2446_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116065","volume":"228","author":"J Zhao","year":"2024","unstructured":"Zhao J, Wu S, Wang D, Edwards H, Thibodeau J, Kim S, et al. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax. Biochem Pharm. 2024;228:116065.","journal-title":"Biochem Pharm"},{"key":"2446_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exphem.2020.01.003","volume":"81","author":"BC Valdez","year":"2020","unstructured":"Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, et al. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Exp Hematol. 2020;81:32\u201341.","journal-title":"Exp Hematol"},{"key":"2446_CR58","first-page":"3893","volume":"8","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Niu X, Walton E, Hurley L, Lin H, Edwards H, et al. Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo. Am J Transl Res. 2016;8:3893\u2013902.","journal-title":"Am J Transl Res"},{"key":"2446_CR59","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood.2020007303","volume":"137","author":"C Herbaux","year":"2021","unstructured":"Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, et al. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021;137:3495\u2013506.","journal-title":"Blood"},{"key":"2446_CR60","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.21037\/atm-21-5066","volume":"9","author":"G Li","year":"2021","unstructured":"Li G, Li D, Yuan F, Cheng C, Chen L, Wei X. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism. Ann Transl Med. 2021;9:1575.","journal-title":"Ann Transl Med"},{"key":"2446_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116663","volume":"276","author":"E Liu","year":"2024","unstructured":"Liu E, Chen Y, Qin M, Yue K, Sun S, Jiang Y, et al. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia. Eur J Med Chem. 2024;276:116663.","journal-title":"Eur J Med Chem"},{"key":"2446_CR62","first-page":"214","volume":"2","author":"RT Marquez","year":"2012","unstructured":"Marquez RT, Xu L. Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy\/apoptosis toggle switch. Am J Cancer Res. 2012;2:214\u201321.","journal-title":"Am J Cancer Res"},{"key":"2446_CR63","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/cdd.2008.185","volume":"16","author":"TR Burton","year":"2009","unstructured":"Burton TR, Gibson SB. The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ. 2009;16:515\u201323.","journal-title":"Cell Death Differ"},{"key":"2446_CR64","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/cdd.2017.22","volume":"24","author":"A Gross","year":"2017","unstructured":"Gross A, Katz SG. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ. 2017;24:1348\u201358.","journal-title":"Cell Death Differ"},{"key":"2446_CR65","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/med.22015","volume":"44","author":"X Palomer","year":"2024","unstructured":"Palomer X, Salvador JM, Grinan-Ferre C, Barroso E, Pallas M, Vazquez-Carrera M. GADD45A: With or without you. Med Res Rev. 2024;44:1375\u2013403.","journal-title":"Med Res Rev"},{"key":"2446_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mrrev.2010.01.009","volume":"704","author":"O Cazzalini","year":"2010","unstructured":"Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res. 2010;704:12\u201320.","journal-title":"Mutat Res"},{"key":"2446_CR67","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1126\/science.6177045","volume":"216","author":"P Martin","year":"1982","unstructured":"Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science. 1982;216:1233\u20135.","journal-title":"Science"},{"key":"2446_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0256-4","volume":"9","author":"JA Machado-Neto","year":"2018","unstructured":"Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, et al. Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms. Cell Death Dis. 2018;9:311.","journal-title":"Cell Death Dis"},{"key":"2446_CR69","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"2446_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1875036201004010005","volume":"4","author":"TL Carrour","year":"2010","unstructured":"Carrour TL, Assou S, Tondeur S, Lhermitte L, Lamb N, Reme T, et al. Amazonia!: an online resource to google and visualize public human whole genome expression data. Open Bioinforma J. 2010;4:5\u201310.","journal-title":"Open Bioinforma J"},{"key":"2446_CR71","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e859.","journal-title":"Cancer Cell"},{"key":"2446_CR72","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526\u201331.","journal-title":"Nature"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02446-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02446-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02446-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T19:08:09Z","timestamp":1743966489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02446-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2446"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02446-4","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,6]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors conducted their research in line with the best practices and codes of conduct of relevant professional bodies and\/or national and international regulatory bodies. All methods were performed in accordance with the relevant guidelines and regulations. All specimens were obtained with informed consent from healthy donors, and the study was approved by the ICB-USP Human Research Ethics Committee (Protocol: 4423074; CAAE: 39510920.1.0000.5467).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"147"}}